Literature DB >> 26113533

CLEC-2: the inside story.

Debra K Newman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26113533      PMCID： PMC4481588          DOI： 10.1182/blood-2015-04-636233

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Arterial thrombosis--insidious, unpredictable and deadly.

Authors:  Shaun P Jackson
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 2.  Platelet ITAM signaling.

Authors:  Wolfgang Bergmeier; Lucia Stefanini
Journal:  Curr Opin Hematol       Date:  2013-09       Impact factor: 3.284

Review 3.  Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2.

Authors:  Y Ozaki; K Suzuki-Inoue; O Inoue
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 4.  Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.

Authors:  David Stegner; Elizabeth J Haining; Bernhard Nieswandt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-12       Impact factor: 8.311

Review 5.  Platelet receptor signaling in thrombus formation.

Authors:  David Stegner; Bernhard Nieswandt
Journal:  J Mol Med (Berl)       Date:  2010-11-07       Impact factor: 4.599

Review 6.  Targeting platelet receptor function in thrombus formation: the risk of bleeding.

Authors:  Frauke Swieringa; Marijke J E Kuijpers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Blood Rev       Date:  2013-12-26       Impact factor: 8.250

Review 7.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

8.  Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization.

Authors:  Viola Lorenz; David Stegner; Simon Stritt; Timo Vögtle; Friedemann Kiefer; Walter Witke; Jürgen Schymeinsky; Steve P Watson; Barbara Walzog; Bernhard Nieswandt
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

9.  Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Michael E Weinblatt; Mark C Genovese; Meilien Ho; Sally Hollis; Krystyna Rosiak-Jedrychowicz; Arthur Kavanaugh; David S Millson; Gustavo Leon; Millie Wang; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 10.  The physiological and pathophysiological roles of platelet CLEC-2.

Authors:  Leyre Navarro-Núñez; Stacey A Langan; Gerard B Nash; Steve P Watson
Journal:  Thromb Haemost       Date:  2013-03-28       Impact factor: 5.249
  10 in total
  2 in total

Review 1.  Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.

Authors:  Georges Jourdi; Marie Lordkipanidzé; Aurélien Philippe; Christilla Bachelot-Loza; Pascale Gaussem
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

Review 2.  Role of platelets and platelet receptors in cancer metastasis.

Authors:  Martin Schlesinger
Journal:  J Hematol Oncol       Date:  2018-10-11       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.